Bartlett EJ - Search Results

1

Optimization of Naked DNA Delivery for Interferon Subtype Immunotherapy in Cytomegalovirus Infection.

Bartlett EJ, Cull VS, Mowe EN, Mansfield JP, James CM. Bartlett EJ, et al. Biol Proced Online. 2003;5:43-52. doi: 10.1251/bpo45. Epub 2003 Feb 17. Biol Proced Online. 2003. PMID: 12734557 Free PMC article.

2

Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis.

Cull VS, Bartlett EJ, James CM. Cull VS, et al. Among authors: bartlett ej. Immunology. 2002 Jul;106(3):428-37. doi: 10.1046/j.1365-2567.2002.01423.x. Immunology. 2002. PMID: 12100732 Free PMC article.

3

Synergy of type I interferon-A6 and interferon-B naked DNA immunotherapy for cytomegalovirus infection.

Bartlett EJ, Cull VS, Brekalo NL, Lenzo JC, James CM. Bartlett EJ, et al. Immunol Cell Biol. 2002 Oct;80(5):425-35. doi: 10.1046/j.1440-1711.2002.01103.x. Immunol Cell Biol. 2002. PMID: 12225378

4

Interferon subtype gene therapy for regulating cytomegalovirus disease.

James CM, Bartlett EJ, Mansfield JP, Cull VS. James CM, et al. Among authors: bartlett ej. Methods Mol Med. 2005;116:207-19. doi: 10.1385/1-59259-939-7:207. Methods Mol Med. 2005. PMID: 16000864

5

Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice.

Cull VS, Broomfield S, Bartlett EJ, Brekalo NL, James CM. Cull VS, et al. Among authors: bartlett ej. Gene Ther. 2002 Oct;9(20):1369-78. doi: 10.1038/sj.gt.3301809. Gene Ther. 2002. PMID: 12365002

6

Type I interferon differential therapy for erythroleukemia: specificity of STAT activation.

Cull VS, Tilbrook PA, Bartlett EJ, Brekalo NL, James CM. Cull VS, et al. Among authors: bartlett ej. Blood. 2003 Apr 1;101(7):2727-35. doi: 10.1182/blood-2002-05-1521. Epub 2002 Nov 21. Blood. 2003. PMID: 12446459 Free article.

7

Type I IFN-beta gene therapy suppresses cardiac CD8+ T-cell infiltration during autoimmune myocarditis.

Bartlett EJ, Lenzo JC, Sivamoorthy S, Mansfield JP, Cull VS, James CM. Bartlett EJ, et al. Immunol Cell Biol. 2004 Apr;82(2):119-26. doi: 10.1046/j.0818-9641.2004.01234.x. Immunol Cell Biol. 2004. PMID: 15061762

8

Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein.

James CM, Abdad MY, Mansfield JP, Jacobsen HK, Vind AR, Stumbles PA, Bartlett EJ. James CM, et al. Among authors: bartlett ej. Vaccine. 2007 Feb 26;25(10):1856-67. doi: 10.1016/j.vaccine.2006.10.038. Epub 2006 Nov 3. Vaccine. 2007. PMID: 17240000

9

Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.

Bartlett EJ, Amaro-Carambot E, Surman SR, Newman JT, Collins PL, Murphy BR, Skiadopoulos MH. Bartlett EJ, et al. Vaccine. 2005 Sep 7;23(38):4631-46. doi: 10.1016/j.vaccine.2005.04.035. Vaccine. 2005. PMID: 15951066

10

A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.

Bartlett EJ, Cruz AM, Boonyaratanakornkit J, Esker J, Castaño A, Skiadopoulos MH, Collins PL, Murphy BR, Schmidt AC. Bartlett EJ, et al. Vaccine. 2010 Jan 8;28(3):767-79. doi: 10.1016/j.vaccine.2009.10.069. Epub 2009 Oct 24. Vaccine. 2010. PMID: 19857454 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters